REGN Regeneron (REGN) Q1 FY26 earnings call
Regeneron delivered a strong start to the year with double-digit revenue and earnings growth, driven by robust commercial performance across key products like DUPIXENT, EYLEA HD, and Libtayo. The company continues to advance a deep pipeline with significant progress in immunology, oncology, and rare diseases, while maintaining a disciplined capital allocation strategy and addressing drug pricing concerns with the U.S. government.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
REGN operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | This call Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Patients DUPIXENT | 1.4M+DUPIXENT is currently the most widely used innovative branded antibody medicine with more than 1.4 million patients on therapy globally.Source: earnings call transcript | 1.4M+Turning to DUPIXENT, which continues to transform the lives of more than 1.4 million patients worldwide with type 2 inflammatory diseases that are currently on treatment.Source: earnings call transcript | 1.5M+Turning to Dupixen, which continues to deliver significant patient benefit to patients globally with more than 1.5 million patients actively treated worldwide, Dupixen has had a tremendous impact across these 9 approved indications, and it is the #1 biologic medicine prescribed by dermatologists and pulmonologist, allergists and ENTs, Second quarter net sales were $6 billion, reflects 38% growth on a constant currency basis and the US, sales grew 42% year-over-year to $4.6 billion, primarily driven by continued growth across our blockbuster indications and uptake in recent launches.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.